Problem

Unstatiq addresses the burden hospitals’ managed-care teams face when reviewing payor contracts and policy manuals that can run to hundreds of pages. The core use case is helping a team turn a large, difficult-to-search contract and policy corpus into usable information during payor-contract review. The economic pain is primarily the labor, time, and delay involved in manually interpreting these documents, although Unstatiq has not published a quantified savings figure for this workflow. Its earlier YC positioning framed the broader healthcare-operations problem as billions of dollars in hospital waste caused by disconnected supply-chain and finance data.

Product / Service

Unstatiq presents an AI-powered contract-review product for hospital managed-care teams. The product is designed to parse and review payor contracts and policies, with the stated benefit of making extensive document sets easier for teams to work through. The company’s public materials do not disclose the underlying integrations, output format, or degree of automation, so the safest description is an AI-assisted document-review platform rather than a fully specified end-to-end contract-management system.

The public site directs prospects to “Meet with Us,” suggesting a founder-led or demo-driven B2B sales motion rather than a transparent self-serve product. Pricing and implementation details are not publicly stated in the available evidence.

Market

Unstatiq competes in healthcare operations software, specifically the intersection of AI contract review, payer-contract analytics, and managed-care workflow tools. The closest visible alternatives are adjacent rather than necessarily identical: PMMC markets hospital contract-management software focused on staff burden and revenue integrity, while Strata Decision offers healthcare contract analytics for modeling payor contracts and analyzing their revenue impact. Unstatiq’s current positioning also appears to represent a repositioning from the broader clinic-finance and supply-chain product described in its older YC profile.

The company was founded in 2022, participated in Y Combinator’s Winter 2023 batch, and is listed by YC as active with a two-person team. The available evidence does not establish a public revenue figure or disclose customer counts, so Unstatiq should be characterized as an active, early-stage company with accelerator validation rather than as demonstrably scaled or definitively pre-revenue.